- HER2 negative
- PD-L1 positive
- ER positive
- HER2 positive
- PR positive
- EGFR positive
- EGFR negative
- PD-L1 negative
- ER negative
- ALK negative
- KRAS positive
- PR negative
- BRAF positive
- CD20 positive
- BRCA1 positive
- ALK positive
- BRCA2 positive
- BRAF negative
- IDH positive
- p16 positive
- ROS1 negative
- CD19 positive
- HLA positive
- HR positive
- MET positive
- MYC positive
- HLA-A positive
- PIK3CA positive
- RET positive
- ROS1 positive
- TP53 positive
- dMMR positive
- IDH negative
- p16 negative
- BCL2 positive
- MET negative
- MSI-H positive
- NF1 positive
- ANA positive
- BCL6 positive
- CD5 positive
- HPV positive
- KRAS negative
- NRAS positive
- NTRK positive
- PALB2 positive
- anti-dsDNA positive
- HBsAg positive
- HPV negative
- MSS positive
- RAS positive
- RET negative
- TP53 negative
- BCR-ABL1 positive
- BRCA1 negative
- CCND1 positive
- CFTR positive
- Ex19del positive
- L858R positive
- ctDNA positive
- pMMR positive
- ABCA4 positive
- BRCA positive
- BRCA2 negative
- FGFR2 positive
- FLT3 positive
- HLA negative
- HLA-A negative
- NTRK negative
- PTEN positive
- RAS negative
- RB1 positive
- TTR positive
- anti-Sm positive
- CD123 positive
- CLDN18.2 positive
- COL7A1 positive
- DMD positive
- MDM2 positive
- MGMT negative
- MMR negative
- Philadelphia chromosome negative
- RB1 negative
- T790M positive
- TROP2 negative
- TROP2 positive
- AKT negative
- APP positive
- C5 positive
- CD19 negative
- CD20 negative
- CD23 positive
- CD30 positive
- CD4 positive
- DLL3 positive
- EBV positive
- ER/PR positive
- FLT3 negative
- FMR1 positive
- HBV DNA negative
- HR negative
- HRAS positive
- MGMT positive
- MMR positive
- MSI-H negative
- NRAS negative
- PSEN1 positive
- PSEN2 positive
- PTCH1 positive
- Philadelphia chromosome positive
- PiZZ positive
- RF positive
- RHO positive
- SMARCA4 positive
- dMMR negative
- t(11;14) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- AKT positive
- ALPL positive
- ALT positive
- APOL1 positive
- ARID1A positive
- ATM positive
- Anti-PLA2R positive
- Aβ1-42 positive
- B7-H3 positive
- CAG repeat in HTT positive
- CDK4 positive
- CEACAM5 positive
- COL1A1 positive
- COL1A2 positive
- EBV DNA positive
- ER or PR positive
- FGFR3 positive
- FOXO1 fusion negative
- FVIII positive
- G719X positive
- GBA positive
- GPC3 positive
- GRN positive
- HBB positive
- HBcAb negative
- HBcAb positive
- HBsAg negative
- HEXA positive
- HEXB positive
- HPV16 positive
- HRD positive
- HbE positive
- HbSS positive
- IGHV negative
- IGHV positive
- JAK2 positive
- KIT positive
- Ki-67 positive
- L861Q positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- MSS negative
- MUC1 positive
- MYC negative
- NF2 positive
- NPM1 positive
- NTRK1 positive
- NY-ESO-1 positive
- PDE6A positive
- PDE6B positive
- PIK3CA negative
- PIK3CD positive
- PIK3R1 positive
- PKLR positive
- PMM2 positive
- PMS2 positive
- PTEN negative
- Ph positive
- RAF positive
- S768I positive
- SMARCB1 negative
- SMN1 positive
- SPINK5 positive
- TET2 positive
- TTR negative
- UBA1 positive
- UGT1A1 positive
- anti-AChR positive
- anti-MuSK positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Smith positive
- core antibody positive
- del(17p) negative
- hepatitis B DNA negative
- kappa light chain positive
- lambda light chain positive
- other sickle cell syndrome variants positive
- p53 positive
- surface antigen positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- ALK TKI Therapy
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Adjuvant Radiation for 4-6 weeks
- Adjuvant Therapy (except reconstruction)
- Adjuvant or Neoadjuvant Chemotherapy with Metastatic Disease Development within 6 Months
- Anthracycline
- Anti-HER2 Therapy
- Anti-Seizure Medications (up to 2 types)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
6853 trials
Trials Without a Placebo
1
2
3
…50